Biosimilars

Lights and shadows in rheumatology

Monica Todoerti, Roberto Caporali, Francesca De Nard, Nicola Boffini, Garifallia Sakellariou, Maria Eva Romano, Lorenzo Cavagna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the last 10 years, the growing approval and marketing of biological agents has significantly ameliorated the outcomes of rheumatoid arthritis and spondyloarthritis patients suffering from active and refractory disease despite conventional treatments. As patent protection of many biopharmaceuticals will expire in the next years, biosimilars could be proximally introduced. Such agents could be marked only when they will be proven, through in vitro and in vivo studies, to be similar enough to the original comparator in term of quality, efficacy and safety. As biosimilars are less expensive than corresponding originators, a wider use of these drugs may substantially cut off the expenditure of biopharmaceuticals. Nevertheless, ongoing debate exists in scientific community: the intrinsic complex and large structure of biologic molecules besides the natural variability in the manufacturing processes might lead to a slightly different product respect to the original one, so that relevant implications for efficacy and safety concerns might arise, especially in the long-term period. Immunogenicity and extended indications of biosimilars represent further matter of discussion, too. Thus, before their approval and marketing, specific guidelines and steps imposed by national and/or international regulatory agencies should be followed along with the respect of scientific societies position in each specific contest.

Original languageEnglish
Article number5518
Pages (from-to)23-27
Number of pages5
JournalRheumatology Reports
Volume6
Issue number1
DOIs
Publication statusPublished - Nov 25 2014

Fingerprint

Biosimilar Pharmaceuticals
Rheumatology
Marketing
Light
International Agencies
Safety
Biological Factors
Health Expenditures
Rheumatoid Arthritis
Guidelines
Pharmaceutical Preparations

Keywords

  • Biosimilars
  • Rheumatoid arthritis
  • Spondyloarthropathies

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Biosimilars : Lights and shadows in rheumatology. / Todoerti, Monica; Caporali, Roberto; De Nard, Francesca; Boffini, Nicola; Sakellariou, Garifallia; Romano, Maria Eva; Cavagna, Lorenzo.

In: Rheumatology Reports, Vol. 6, No. 1, 5518, 25.11.2014, p. 23-27.

Research output: Contribution to journalArticle

Todoerti, Monica ; Caporali, Roberto ; De Nard, Francesca ; Boffini, Nicola ; Sakellariou, Garifallia ; Romano, Maria Eva ; Cavagna, Lorenzo. / Biosimilars : Lights and shadows in rheumatology. In: Rheumatology Reports. 2014 ; Vol. 6, No. 1. pp. 23-27.
@article{55b3067e69c3433b818d2775539f99ed,
title = "Biosimilars: Lights and shadows in rheumatology",
abstract = "In the last 10 years, the growing approval and marketing of biological agents has significantly ameliorated the outcomes of rheumatoid arthritis and spondyloarthritis patients suffering from active and refractory disease despite conventional treatments. As patent protection of many biopharmaceuticals will expire in the next years, biosimilars could be proximally introduced. Such agents could be marked only when they will be proven, through in vitro and in vivo studies, to be similar enough to the original comparator in term of quality, efficacy and safety. As biosimilars are less expensive than corresponding originators, a wider use of these drugs may substantially cut off the expenditure of biopharmaceuticals. Nevertheless, ongoing debate exists in scientific community: the intrinsic complex and large structure of biologic molecules besides the natural variability in the manufacturing processes might lead to a slightly different product respect to the original one, so that relevant implications for efficacy and safety concerns might arise, especially in the long-term period. Immunogenicity and extended indications of biosimilars represent further matter of discussion, too. Thus, before their approval and marketing, specific guidelines and steps imposed by national and/or international regulatory agencies should be followed along with the respect of scientific societies position in each specific contest.",
keywords = "Biosimilars, Rheumatoid arthritis, Spondyloarthropathies",
author = "Monica Todoerti and Roberto Caporali and {De Nard}, Francesca and Nicola Boffini and Garifallia Sakellariou and Romano, {Maria Eva} and Lorenzo Cavagna",
year = "2014",
month = "11",
day = "25",
doi = "10.4081/rr.2014.5518",
language = "English",
volume = "6",
pages = "23--27",
journal = "Rheumatology Reports",
issn = "2036-7511",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - Biosimilars

T2 - Lights and shadows in rheumatology

AU - Todoerti, Monica

AU - Caporali, Roberto

AU - De Nard, Francesca

AU - Boffini, Nicola

AU - Sakellariou, Garifallia

AU - Romano, Maria Eva

AU - Cavagna, Lorenzo

PY - 2014/11/25

Y1 - 2014/11/25

N2 - In the last 10 years, the growing approval and marketing of biological agents has significantly ameliorated the outcomes of rheumatoid arthritis and spondyloarthritis patients suffering from active and refractory disease despite conventional treatments. As patent protection of many biopharmaceuticals will expire in the next years, biosimilars could be proximally introduced. Such agents could be marked only when they will be proven, through in vitro and in vivo studies, to be similar enough to the original comparator in term of quality, efficacy and safety. As biosimilars are less expensive than corresponding originators, a wider use of these drugs may substantially cut off the expenditure of biopharmaceuticals. Nevertheless, ongoing debate exists in scientific community: the intrinsic complex and large structure of biologic molecules besides the natural variability in the manufacturing processes might lead to a slightly different product respect to the original one, so that relevant implications for efficacy and safety concerns might arise, especially in the long-term period. Immunogenicity and extended indications of biosimilars represent further matter of discussion, too. Thus, before their approval and marketing, specific guidelines and steps imposed by national and/or international regulatory agencies should be followed along with the respect of scientific societies position in each specific contest.

AB - In the last 10 years, the growing approval and marketing of biological agents has significantly ameliorated the outcomes of rheumatoid arthritis and spondyloarthritis patients suffering from active and refractory disease despite conventional treatments. As patent protection of many biopharmaceuticals will expire in the next years, biosimilars could be proximally introduced. Such agents could be marked only when they will be proven, through in vitro and in vivo studies, to be similar enough to the original comparator in term of quality, efficacy and safety. As biosimilars are less expensive than corresponding originators, a wider use of these drugs may substantially cut off the expenditure of biopharmaceuticals. Nevertheless, ongoing debate exists in scientific community: the intrinsic complex and large structure of biologic molecules besides the natural variability in the manufacturing processes might lead to a slightly different product respect to the original one, so that relevant implications for efficacy and safety concerns might arise, especially in the long-term period. Immunogenicity and extended indications of biosimilars represent further matter of discussion, too. Thus, before their approval and marketing, specific guidelines and steps imposed by national and/or international regulatory agencies should be followed along with the respect of scientific societies position in each specific contest.

KW - Biosimilars

KW - Rheumatoid arthritis

KW - Spondyloarthropathies

UR - http://www.scopus.com/inward/record.url?scp=84925527296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925527296&partnerID=8YFLogxK

U2 - 10.4081/rr.2014.5518

DO - 10.4081/rr.2014.5518

M3 - Article

VL - 6

SP - 23

EP - 27

JO - Rheumatology Reports

JF - Rheumatology Reports

SN - 2036-7511

IS - 1

M1 - 5518

ER -